All posts by: Admin

About Admin

CannPal Commences Phase 1B Study for Lead Drug Candidate CPAT-01D

Animal health company CannPal Animal Therapeutics Limited (ASX:CP1) (“CannPal” or “the Company”) is pleased to announce that it has commenced Phase 1B of the Pharmacokinetic and Safety study for CPAT-01D, a cannabis-derived veterinary medicine being developed as a pain control in dogs. Key Highlights Commenced Phase 1B of the Pharmacokinetic and Safety study for CPAT-01D, a cannabis-derived … Continue reading

September 5, 2018 Latest News, News

CannPal Enters MOU with The University of Melbourne to Research Epilepsy Treatment for Dogs

8th August 2018: Animal health company CannPal Animal Therapeutics Limited (ASX:CP1) (“CannPal” or “the Company”) is pleased to announce it has entered into a Memorandum of Understanding (MOU) with The University of Melbourne (‘the University’) to broaden the Company’s research pipeline. Key Highlights CannPal has entered into a Memorandum of Understanding with The University of Melbourne for veterinary … Continue reading

August 8, 2018 Latest News, News

CannPal Receives Ethics Approvals for Phase 1B Study in Dogs

Animal health company CannPal Animal Therapeutics Limited (ASX:CP1) (“CannPal” or “the Company”) is pleased to announce it has received ethics approval to advance its clinical development plans for CPAT-01, a pain control being developed for cats and dogs. Key Highlights CannPal has received ethics approvals to advance the development of its lead drug candidate, CPAT-01, a pain … Continue reading

August 2, 2018 Latest News, News

CannPal Enters into Research Agreement with Eurofins Animal Health for Cat Drug

Animal health company CannPal Animal Therapeutics Limited (ASX:CP1) (“CannPal” or “the Company”) is pleased to announce it has entered into a research services agreement with Eurofins Animal Health Pty Ltd to develop a cannabis-derived pain treatment for cats. Key Highlights CannPal has entered into a research services agreement with veterinary research organisation, Eurofins Animal Health Pty Ltd … Continue reading

July 8, 2018 Latest News, News

CannPal Receives Funding for Research Collaboration with CSIRO

Animal health company CannPal Animal Therapeutics Limited (ASX:CP1) (“CannPal” or “the Company”) is pleased to announce that it has entered into a research agreement with the Commonwealth Scientific and Industrial Research Organisation (CSIRO) under the CSIRO Kick-Start initiative. Key Highlights CannPal has entered into a research agreement with CSIRO, as part of the national science organisation’s CSIRO … Continue reading

June 28, 2018 Latest News, News

Market Update on CPAT-01 & Pharmacokinetic Study

Animal health company CannPal Animal Therapeutics Limited (ASX:CP1) (“CannPal” or “the Company”) is pleased to update the market on the recently completed Pharmacokinetic and Safety study for CPAT-01, the Company’s lead pharmaceutical in development as a pain control for dogs. Key Highlights CannPal has successfully completed Phase 1A of the Pharmacokinetic and Safety Study for CPAT-01 with … Continue reading

June 18, 2018 Latest News, News

CannPal Enters into Manufacturing Agreement with Jaychem Industries Ltd

29th May 2018: Animal health company CannPal Animal Therapeutics Limited (ASX:CP1) (“CannPal” or “the Company”) is pleased to announce that it has entered into a strategic manufacturing agreement with Jaychem Industries Ltd (“Jaychem”). Key Highlights CannPal has entered into a manufacturing agreement with New Zealand based veterinary contract manufacturing organization, Jaychem Industries Ltd Jaychem is … Continue reading

May 18, 2018 Latest News, News

CannPal Successfully Imports Cannabis Oils for Clinical Trial of Lead Drug Candidate

Key Highlights CannPal has been granted export permits by Health Canada for its medical cannabis oil formulations Oils have now arrived in Sydney, Australia and are in transit to a purpose-built research facility for the clinical phase of the Company’s research cGMP accredited licensed producer Aphria Inc (TSE:APH), has provided the clinical trial material for … Continue reading

March 27, 2018 Latest News, News

CannPal Granted SME Status by the European Medicines Agency (EMA)

Key Highlights CannPal has received confirmation of SME (Small and Medium size Enterprises) status,with the European Medicines Agency (EMA)  The European Medicines Agency is the European Union agency responsible for the evaluation and regulation of veterinary medicinal products (VMP’s) in Europe; The SME status allows CannPal a line of communication with the EMA for the … Continue reading

December 18, 2017 Latest News, News